Nitrogen Containing Patents (Class 514/497)
  • Patent number: 8658193
    Abstract: Technologies are described herein for styptic compounds comprising a hemostatic or styptic agent suspended within a hydrophobic carrier medium. Example carrier mediums may include waxes, lipids, oils, or combinations thereof. The compound may be a semisolid at room temperature and soft enough to be easily dispensed and formed into or onto bleeding tissue of an animal or human. The hydrophobic qualities of the carrier medium can protect the styptic agent from absorbing moisture. The carrier medium can mechanically support positioning treatments adjacent to the bleeding tissue. The carrier medium can further serve to mechanically seal the tissue to aid in hemostasis while also protecting the tissue from debris and contamination. The carrier medium can aid in maintaining moisture within the tissue. Slurry-based manufacturing processes can support a substantially homogeneous dispersal of styptic agent throughout the carrier medium.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 25, 2014
    Inventor: Robert J. Greenwald
  • Publication number: 20130060208
    Abstract: The present invention relates to wound care products, devices and methods incorporating acetic acid for the treatment of bacterial infections, in particular bacterial biofilm infections. In particular it relates to a wound care product comprising acetic acid, wherein the product comprises at least one further antibacterial compound; a delivery system comprising a container connected to a means of delivery which is connected to a pad, wherein said container comprises a composition comprising acetic acid and said pad comprises a self-adhesive material; a kit comprising a dressing and an adhesive membrane, wherein the dressing comprises a composition comprising acetic acid; a method of treating a wound comprising a) applying acetic acid to the wound and b) applying a negative pressure to the wound.
    Type: Application
    Filed: December 21, 2010
    Publication date: March 7, 2013
    Applicants: RIGSHOSPITALET, COPENHAGEN UNIVERSITY HOSPITAL, BISPEBJERG HOSPITAL, DANMARKS TEKNISKE UNIVERSITET
    Inventors: Michael Christian Givskov, Thomas Bjarnsholt, Klaus Kirketerp-Møller
  • Patent number: 8357719
    Abstract: A drug having a muscle relaxing effect can be prepared by binding negatively charged gold nanoparticles having a size of 1.4 nm fitted to synaptic clefts to choline through ionic bonds, thereby inducing gold-sulfur bonds in the Cys loop of an acetylcholine receptor in neuromuscular junction, and thus blocking the electric current induced in signal transduction from a nerve to a muscle, thereby blocking neuromuscular transmission chemically and physically. When the reverse is administered after surgery, the gold-sulfur bonds are broken due to the re-flow of the electric current, and thus the gold nanoparticles are again released and metabolized into neuromuscular junction. Further, such muscle relaxing effect can be applied as an anticonvulsant.
    Type: Grant
    Filed: November 22, 2007
    Date of Patent: January 22, 2013
    Inventor: Chur Chin
  • Patent number: 8349887
    Abstract: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, gastrointestinal disorders, cardiovascular disorders, obesity and obesity-associated disorders, central nervous system disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: January 8, 2013
    Assignee: Tranzyme Pharma Inc.
    Inventors: Graeme L. Fraser, Hamid R. Hoveyda, Mark L. Peterson
  • Patent number: 8211873
    Abstract: This invention relates to certain chirally-correct mitoprotectant phosphorylated heterocyclic agents [formula (I)], which are useful for the treatment of dermatological disorders that include challenged skin from cancer, diabetes, radiation treatments, chemotherapy, and sun-burn; mitochondrial dysfunction; age spots; acne, loss of cellular antioxidants; skin changes associated with aging including collagen loss, loss of skin pliability, loss of skin suppleness, skin wrinkles and fine lines, oxidation, damage from radiation, damage from free radicals, and damage from UV; dry skin; xerosis; ichthyosis; dandruff; brownish spots; keratoses; melasma; lentigines; liver spots; skin pigmentation including pigmented spots, dark circles under the eyes, darkened skin, and blemishes; oily skin; warts; eczema; pruritic skin; psoriasis; inflammatory dermatoses; topical inflammation; disturbed keratinization; scalp dryness; skin depigmentation, and combinations thereof;
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: July 3, 2012
    Assignee: Island Kinetics, inc.
    Inventors: Shyam K Gupta, Linda Walker
  • Patent number: 7732486
    Abstract: Anhydrous silver dihydrogen citrate compositions comprise silver dihydrogen citrate and citric acid. The anhydrous compositions can be prepared by freeze-drying. The anhydrous compositions can be reconstituted with a suitable diluent to form silver dihydrogen citrate compositions. The anhydrous compositions can be reconstituted and applied to a variety of substrates to impart an antimicrobial effect on the substrates.
    Type: Grant
    Filed: March 27, 2007
    Date of Patent: June 8, 2010
    Assignee: Pure Bioscience
    Inventor: Andrew B. Arata
  • Patent number: 7569558
    Abstract: The present invention relates to a method for topical delivery of trace metals for the modulation of certain metalloenzymes. The method of topical delivery of the present invention comprises; (i) mixing of a trace metal salt of a phosphorylated nitrogen heterocyclic base complexed with a chelating agent [Figure l], and (ii) a carrier, and (iii) topical application of said mixture. The modulation of metalloenzymes such as Superoxide Dismutase, Elastase, Tyrosinase, Matrix metalloproteases, and Ubiquitin-Proteasome pathway by the methods of the present invention is useful for providing anti-inflammatory, skin whitening, wrinkles reduction, skin aging control, cellular antioxidant, acne control, hair growth modulation, and skin damage control benefits.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: August 4, 2009
    Assignee: Bioderm Research
    Inventor: Shyam K Gupta
  • Patent number: 6939566
    Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: September 6, 2005
    Inventors: Kareem I. Batarseh, Marwan Al-Kayed
  • Patent number: 6630172
    Abstract: Disinfectant formulations are described which are preferably ecologically friendly and non-toxic to mammals and plants, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having at least one metal ion which is microbicidal to at least one microorganism and potassium sodium tartrate in some form. When potassium sodium tartrate is used with these metal ions, it enhances the complex-forming properties of such metal complexes while concurrently increases their efficacy and potency at the same level of metal ion concentrations. These microbicidal formulations can be diluted in suitable proportions into aqueous systems to produce the desired dosages for each individual case, depending on the level and the severity of the contamination. The microbicidal formulations can be applied by conventional methods, e.g., spraying, soaking, fogging, impregnation, and the like.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: October 7, 2003
    Inventor: Kareem I. Batarseh
  • Patent number: 6426093
    Abstract: A biocidal composition composed of a ternary complex of a negatively-charged biocide, a transition metal ion and chelator has synergistic biocidal effects as compared with a composition of each of the components alone. The chelator is preferably a neutral or positively-charged chelator. The ternary complex may be used for killing or inhibiting the growth of living cells.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: July 30, 2002
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Mordechai Chevion, Benzhan Zhu, Svetlana Schechtman
  • Patent number: 6391879
    Abstract: A therapeutic solution and application procedure for curing and preventing nail fungus and athlete's foot infections or Onychomycosis comprising a combination of an anti-fungal agent with DMSO in a anhydrous solution of Polyglycol. The DMSO acts as a solvent so that active anti-fungal agents such as Tolnaftate can be delivered directly to fungal infected areas under and around the nail and other areas prone to topical tinea infections. The DMSO, and Tolnaftate dissolved in a viscous solution of polyglycol so that the combined ingredients may be applied directly to the affected areas with superior penetration. The therapeutic solution is formulated by dissolving the Tolnaftate into the DMSO, and then combining the DMSO and polyglycol solutions together to form the therapeutic solution. Repeated applications of the resulting solution on Onychomycosis infected nails over one 4-6 week period yields satisfactory result rates as high as 85-90% without augmenting the therapy with systemic drugs.
    Type: Grant
    Filed: August 17, 2000
    Date of Patent: May 21, 2002
    Assignee: Astan, Inc.
    Inventor: Stanley Forrest Reeves
  • Patent number: 6242009
    Abstract: Microbicidal formulations are described which are preferably ecologically friendly and non-toxic to mammals, and are highly effective against a broad spectrum of detrimental pathogenic microorganisms. The microbicidal formulation contains complexes having the formula R-M, wherein R is at least one organic chelating moiety and M is at least one metal ion which is microbicidal to at least one microorganism. These complexes can disrupt microorganism activities by penetrating the natural protecting bio-films of such microorganisms through the reaction of the R-group with the organic constituents of these microorganisms while releasing M into their intra-cellular media. Thus, this process exhibits its biocidal activities from the inside-out, contrary to other methods which rely on damaging the protective biofilms.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: June 5, 2001
    Inventors: Kareem I. Batarseh, Marwan Al-Kayed
  • Patent number: 6207699
    Abstract: Numerous studies have documented that medications which increase brain serotonin (5-HT) are effective anorectic agents which help obese patients lose weight and which also decrease craving for sweets and carbohydrates. Evidence from other studies also indicate that increases in brain 5-HT may help decrease craving for alcohol and cocaine. 5-hydroxy-L-tryptophan, abbreviated 5-HTP, is the immediate precursor of serotonin (5-HT). When administered in combination with an inhibitor of peripheral decarboxylase such as carbidopa, 5-HTP increases brain serotonin. Increases in synaptic 5-HT decreases the firing rate of 5-HT neurons via stimulation of inhibitory 5-HT1a receptors located on the cell bodies in the raphe. This serves as a negative feedback loop. The clinically available beta adreneric receptor antagonist medication pindolol is also a 5-HT1a antagonist, and can be used to increase the ability of 5-HTP to increase brain 5-HT. Previous studies with 5-HTP used doses exceeding 50 mg per day.
    Type: Grant
    Filed: June 18, 1999
    Date of Patent: March 27, 2001
    Inventor: Richard Brian Rothman
  • Patent number: 6090811
    Abstract: A novel use for the class of biologically active bis-heterocyclic, e.g., bis-indole alkaloid compounds, which have been named topsentins, bromotopsentins, homocarbonyltopsentins, nortopsentins, hamacanthins, bis-indole ethylamines, or dragmacidins, pharmaceutical compositions containing the compounds, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-neurogenic inflammatory properties exhibited by the bis-indole compounds and their analogs.
    Type: Grant
    Filed: July 16, 1999
    Date of Patent: July 18, 2000
    Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the Univ. of California
    Inventors: Robert S. Jacobs, Shirley A. Pomponi, Sarath P. Gunasekera, Amy E. Wright
  • Patent number: 5985917
    Abstract: This invention is directed to a pharmacologically acceptable composition for inhibiting nitric oxide synthase in a mammal, which includes a mercapto or seleno derivative and a pharmaceutically acceptable carrier. The invention also concerns a method of inhibiting nitric oxide synthase, selectively inhibiting the inducible isoform of nitric oxide synthase, and treating various conditions where there is an advantage in inhibiting nitric oxide biosynthesis. The method includes the step of administering to a mammal a mercapto or seleno derivative in pure form or in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: November 16, 1999
    Assignee: Children's Hospital Medical Center
    Inventors: Garry J. Southan, Andrew L. Salzman, Csaba Szabo
  • Patent number: 5955053
    Abstract: The present invention relates to novel metal chelates, exemplified as technetium-99m or rhenium chelates, and to the process of preparing such metal chelates from corresponding ligands. These ligands and their corresponding metal chelates are synthesized to have a cysteinylethylene (EC) structure, a thioacetamidethiourea (TATU) structure, or a dithiourea (DTU) structure. The present invention further relates to a pharmaceutical composition comprising a metal chelate, for example, a .sup.99m Tc-chelate, to the use of the composition for renal imaging and examination of renal function, and to a kit for preparing such a composition prior to use.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: September 21, 1999
    Assignee: Emory University
    Inventors: Luigi Gaetano Marzilli, Malgorzata Lipowska, Lory Hansen, Andrew Taylor, Jr.
  • Patent number: 5955462
    Abstract: A novel use for the class of biologically active bis-heterocyclic, e.g., bis-indole alkaloid compounds, which have been named topsentins, bromotopsentins, homocarbonyltopsentins, nortopsentins, hamacanthins, bis-indole ethylamines, or dragmacidins, pharmaceutical compositions containing the compounds, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-neurogenicinflammatory properties exhibited by the bis-indole compounds and their analogs.
    Type: Grant
    Filed: October 31, 1997
    Date of Patent: September 21, 1999
    Assignees: Harbor Branch Oceanographic Institution, Inc., Regents of the Univ. of California
    Inventors: Robert S. Jacobs, Shirley A. Pomponi, Sarath P. Gunasekera, Amy E. Wright
  • Patent number: 5916356
    Abstract: This invention relates to preservative compositions which comprise a biocidal metal compound and an fungicidal compound containing a triazole group. Methods of treating wood with the composition are also described.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: June 29, 1999
    Assignee: Hickson International PLC
    Inventors: Gareth Williams, Judith Ann Cornfield, Janet Brown, Neil Patrick Ryan
  • Patent number: 5676923
    Abstract: Diethylenetriaminepentaacetic acid monoamide derivatives, their complexes and complex salts, containing an element of atomic numbers 21-29, 31, 32, 39, 42-44, 49 or 57-83, pharmaceutical agents containing these compounds, their use as contrast media and process for their production.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 14, 1997
    Assignee: Schering Aktiengesellschaft
    Inventors: Johannes Platzek, Ulrich Niedballa, Peter Mareski, Bernd Raduchel, Hanns-Joachim Weinmann, Andreas Muhler, Bernd Misselwitz
  • Patent number: 5290777
    Abstract: A novel use for the class of biologically active bis-indole alkaloid compounds, which have been named topsentins, nortopsentins, or dragmacidins, pharmaceutical compositions containing them, methods of producing the compounds, and methods of using the compounds are disclosed. Specifically, the novel utility pertains to the anti-inflammatory properties exhibited by the bis-indole compounds and their analogs.
    Type: Grant
    Filed: February 24, 1993
    Date of Patent: March 1, 1994
    Assignees: Regents of the Univ. of California, Harbor Branch Oceanographic Inst. Inc.
    Inventors: Oliver J. McConnell, Gabriel Saucy, Robert Jacobs